Abstract
Purpose
Glioma is the most common malignant primary tumor in the central nervous system (CNS). KIF3C, a motor protein of the kinesin superfamily, is highly expressed in the CNS. Although KIF3C has been identified as a potential therapeutic target in malignant cancers, the expression and function of KIF3C in glioma remains unclear.
Methods
The clinical characteristics of 53 patients with graded glioma (WHO I–IV) were analyzed in this study. The expression of KIF3C in glioma was evaluated by immunohistochemistry (IHC). Survival analysis was compared between higher and lower KIF3C expression groups. Data regarding the expression of KIF3C and survival analysis were also confirmed using the database from The Cancer Genome Atlas (TCGA). The potential mechanism of the regulation of tumor growth by KIF3C was investigated by an analysis of the public database from Oncomine.
Results
Expression of the KIF3C protein was higher in the low-grade glioma (LGG) group (n = 20) than that in the high-grade glioma (HGG) group (n = 33) (P < 0.05). Glioma patients with higher expression of KIF3C had longer survival time (P < 0.05). The subgroup analysis showed that higher KIF3C expression predicted longer survival time in the LGG group (P < 0.05). These clinical results were consistent with those in the TCGA database. Bioinformatics analysis showed that the KIF3C mRNA expression was upregulated significantly in response to PI3K/AKT/mTOR pathway inhibition.
Conclusion
This study demonstrated that KIF3C might inhibit glioma growth to prolong survival time by regulating the PI3K/AKT/mTOR pathway, providing a potential therapeutic target in glioma.
Similar content being viewed by others
References
Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14:41–49. https://doi.org/10.1093/neuonc/nos218
Olar A, Aldape KD (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232:165–177. https://doi.org/10.1002/path.4282
Jaoude DA, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF Jr (2019) Glioblastoma and increased survival with longer chemotherapy duration. Kans J Med 12(3):65–69
Saito T, Sugiyama K, Takeshima Y, Amatya VJ, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K (2018) Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurosurg 128:679–684. https://doi.org/10.3171/2016.11.JNS162326
Goldstein LS, Yang Z (2000) Microtubule-based transport systems in neurons: the roles of kinesins and dyneins. Annu Rev Neurosci 23:39–71. https://doi.org/10.1146/annurev.neuro.23.1.39
Hirokawa N (1998) Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 279:519–526. https://doi.org/10.1126/science.279.5350.519
Hirokawa N, Noda Y (2008) Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics. Physiol Rev 88:1089–1118. https://doi.org/10.1152/physrev.00023.2007
Hirokawa N, Takemura R (2005) Molecular motors and mechanisms of directional transport in neurons. Nat Rev Neurosci 6:201–214. https://doi.org/10.1038/nrn1624
Malicki J, Besharse JC (2012) Kinesin-2 family motors in the unusual photoreceptor cilium. Vision Res 75:33–36. https://doi.org/10.1016/j.visres.2012.10.008
Yang Z, Roberts EA, Goldstein LS (2001) Functional analysis of mouse kinesin motor Kif3C. Mol Cell Biol 21:5306–5311. https://doi.org/10.1128/MCB.21.16.5306-5311.2001
Teng J, Rai T, Tanaka Y, Takei Y, Nakata T, Hirasawa M, Kulkarni AB, Hirokawa N (2005) The KIF3 motor transports N-cadherin and organizes the developing neuroepithelium. Nat Cell Biol 7:474–482. https://doi.org/10.1038/ncb1249
Keil R, Kiessling C, Hatzfeld M (2009) Targeting of p0071 to the midbody depends on KIF3. J Cell Sci 122:1174–1183. https://doi.org/10.1242/jcs.045377
Sardella M, Navone F, Rocchi M, Rubartelli A, Viggiano L, Vignali G, Consalez GG, Sitia R, Cabibbo A (1998) KIF3C, a novel member of the kinesin superfamily: sequence, expression, and mapping to human chromosome 2 at 2p23. Genomics 47:405–408. https://doi.org/10.1006/geno.1997.5123
Yang Z, Goldstein LS (1998) Characterization of the KIF3C neural Kinesin-like motor from mouse. Mol Biol Cell 9:249–261. https://doi.org/10.1091/mbc.9.2.249
Gumy LF, Chew DJ, Tortosa E, Katrukha EA, Kapitein LC, Tolkovsky AM, Hoogenraad CC, Fawcett JW (2013) The kinesin-2 family member KIF3C regulates microtubule dynamics and is required for axon growth and regeneration. J Neurosci 33:11329–11345. https://doi.org/10.1523/JNEUROSCI.5221-12.2013
Wang C, Wang C, Wei Z, Li Y, Wang W, Li X, Zhao J, Zhou X, Qu X, Xiang F (2015) Suppression of motor protein KIF3C expression inhibits tumor growth and metastasis in breast cancer by inhibiting TGF-β signaling. Cancer Lett 368:105–114. https://doi.org/10.1016/j.canlet.2015.07.037
Navone F, Consalez GG, Sardella M, Caspani E, Pozzoli O, Frassoni C, Morlacchi E, Sitia R, Sprocati T, Cabibbo A (2001) Expression of KIF3C kinesin during neural development and in vitro neuronal differentiation. J Neurochem 77:741–753. https://doi.org/10.1046/j.1471-4159.2001.00277.x
Liu Z, Rebowe RE, Wang Z, Li Y, Wang Z, DePaolo JS, Guo J, Qian C, Liu W (2014) KIF3a promotes proliferation and invasion via Wnt signaling in advanced prostate cancer. Mol Cancer Res 12:491–503. https://doi.org/10.1158/1541-7786.MCR-13-0418
Huang X, Liu F, Zhu C, Cai J, Wang H, Wang X, He S, Liu C, Yao L, Ding Z, Zhang Y, Zhang T (2014) Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation. Dig Dis Sci 59:795–806. https://doi.org/10.1007/s10620-013-2969-2
De S, Cipriano R, Jackson MW, Stark GR (2009) Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 69:8035–8042. https://doi.org/10.1158/0008-5472.CAN-09-1224
Son HJ, Choi EJ, Yoo NJ, Lee SH (2019) Somatic frameshift mutations of cancer-related genes KIF3C and BARD1 in colorectal cancers. Pathol Res Pract 215:152579. https://doi.org/10.1016/j.prp.2019.152579
Harada M, Ishihara Y, Itoh K, Yamanaka R (2007) Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep 17:629–636. https://doi.org/10.3892/or.17.3.629
Schmid RS, Simon JM, Vitucci M, McNeill RS, Bash RE, Werneke AM, Huey L, White KK, Ewend MG, Wu J, Miller CR (2016) Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. Neuro Oncol 18:962–973. https://doi.org/10.1093/neuonc/nov321
Muresan V, Abramson T, Lyass A, Winter D, Porro E, Hong F, Chamberlin NL, Schnapp BJ (1998) KIF3C and KIF3A form a novel neuronal heteromeric kinesin that associates with membrane vesicles. Mol Biol Cell 9:637–652. https://doi.org/10.1091/mbc.9.3.637
Gersey Z, Osiason AD, Bloom L, Shah S, Thompson JW, Bregy A, Agarwal N, Komotar RJ (2019) Therapeutic targeting of the notch pathway in glioblastoma multiforme. World Neurosurg. https://doi.org/10.1016/j.wneu.2019.07.180
Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L (2016) PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7:33440–33450. https://doi.org/10.18632/oncotarget.7961
Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP (2017) Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 16:100. https://doi.org/10.1186/s12943-017-0670-3
Wojtas B, Gielniewski B, Wojnicki K, Maleszewska M, Mondal SS, Nauman P, Grajkowska W, Glass R, Schüller U, Herold-Mende C, Kaminska B (2019) Gliosarcoma is driven by alterations in PI3K/Akt, RAS/MAPK pathways and characterized by collagen gene expression signature. Cancers 11(3):E284. https://doi.org/10.3390/cancers11030284
Acknowledgements
This study is supported by Grants from the Foundation of Shanghai anti cancer association (No. SACA-CY19C05), the National Natural Science Foundation of China (No. 81802494) the Shanghai Natural Science Foundation (No. 16ZR1406300) and Wu Jieping Medical Foundation (320.6750.17150).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The present study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center. All procedures performed in the present study were in accordance with the 1964 Helsinki Declaration and its later amendments.
Informed consent
Informed consent was not sought, since a retrospective design was used.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gao, Y., Li, L., Zheng, H. et al. KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway. J Neurooncol 146, 513–521 (2020). https://doi.org/10.1007/s11060-020-03399-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-020-03399-7